Jon Congleton News Today

RADNOR, Pa., Jan. 29, 2024 -- Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other...

RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused o...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) CEO Jon Congleton acquired 4,250 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The shares were purchased at an average cost of $5.97 per share, for a total transaction of $25,372.50. Following the completion of the acquisition, the chief executive officer now directly […]

Operator: Good afternoon, ladies and gentlemen, and welcome to the Mineralys Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions].

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) has received an average recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have covered the stock in the last year […]

Mineralys Therapeutics, Inc. presented final results from the Target-HTN Phase 2 trial of lorundrostat at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, and simultaneously published in the Journal of the American Medical Association (JAMA).

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.

– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure , including an enhanced response in individuals with...

Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have covered the stock […]

29.08.2023 - RADNOR, Pa., Aug. 29, 2023 (GLOBE NEWSWIRE) - Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced ...